RANBP9 and non-small cell lung carcinoma: RANBP9 protein expression is high in advanced NSCLC, and patients expressing higher levels of RANBP9 protein have worse outcomes when treated with platinum-based regimens, which is in line with the hypothesis that RANBP9 is protective of cancer cells when subjected to DNA damage [14].